Αρχική World News FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met... World News FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression Από Ogkologos - 13 Ιουνίου, 2025 903 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Generic Enzalutamide 9 Αυγούστου, 2024 EMA Recommends Granting a Marketing Authorisation for Fedratinib 23 Δεκεμβρίου, 2020 Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients... 28 Σεπτεμβρίου, 2026 ESMO contributes to discussions on the future of cancer care at... 7 Οκτωβρίου, 2026 Φόρτωση περισσοτέρων HOT NEWS Improving cancer care for the LGBTQ+ community ΚΑΡΚΙΝΟΣ ΕΝΔΟΜΗΤΡΙΟΥ The Horror Story Of What Can Happen When You Don’t Pay... Significant iDFS Benefit with Adding Ribociclib to a Nonsteroidal Aromatase Inhibitor...